- Home
- Companies
- LAVA Therapeutics N.V.
- Articles
- Potent anti-tumor activity against ...
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Courtesy of LAVA Therapeutics N.V.
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity
- CD1d can be expressed by several hematologic malignancies
- Bispecific Vγ9Vδ2-T cell engager
- Unique ability to also trigger type 1 natural killer T (NKT) cells
- LAVA-051: humanized CD1d-Vδ2 bsVHH
-
Most popular related searches
Customer comments
No comments were found for Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d. Be the first to comment!